SG11201903012RA - Anti-c1s antibodies and methods of use thereof - Google Patents
Anti-c1s antibodies and methods of use thereofInfo
- Publication number
- SG11201903012RA SG11201903012RA SG11201903012RA SG11201903012RA SG11201903012RA SG 11201903012R A SG11201903012R A SG 11201903012RA SG 11201903012R A SG11201903012R A SG 11201903012RA SG 11201903012R A SG11201903012R A SG 11201903012RA SG 11201903012R A SG11201903012R A SG 11201903012RA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- antibodies
- present disclosure
- disclosure provides
- san francisco
- Prior art date
Links
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 150000007513 acids Chemical class 0.000 abstract 1
- 230000024203 complement activation Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Abstract
WO 18/07 167 6 Al (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 19 April 2018 (19.04.2018) WIP0 1 PCT omit VIII °nolo mom VIII ioo mom° oimIE (10) International Publication Number WO 2018/071676 Al (51) International Patent Classification: A01N 1/02 (2006.01) A61K 39/395 (2006.01) A61B 5/055 (2006.01) (21) International Application Number: PCT/US2017/056349 (22) International Filing Date: 12 October 2017 (12.10.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/407,390 12 October 2016 (12.10.2016) US (71) Applicant: BIOVERATIV USA INC. [US/US]; 951 Gate- way Blvd., South San Francisco, CA 94080 (US). (72) Inventors: PANICKER, Sandip; 951 Gateway Boulevard, South San Francisco, CA 94080 (US). PARRY, Graham; 951 Gateway Boulevard, South San Francisco, CA 94080 (US). STAGLIANO, Nancy, E.; 951 Gateway Boulevard, South San Francisco, CA 94080 (US). (74) Agent: KIM, Ji-Eun et al.; Sterne, Kessler, Goldstein & Fox P.L.L.C., 1100 New York Avenue, NW, Washington, DC 20005 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a)) (54) Title: ANTI-C1S ANTIBODIES AND METHODS OF USE THEREOF (57) : The present disclosure provides antibodies that specifically bind complement pathway component Cls. The present disclosure provides nucleic acids comprising nucleotide sequences encoding the anti-Cls antibodies; and host cells comprising the nu- cleic acids. The present disclosure provides compositions comprising the anti-Cls antibodies. The present disclosure provides methods of use of the anti-Cls antibodies.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662407390P | 2016-10-12 | 2016-10-12 | |
| PCT/US2017/056349 WO2018071676A1 (en) | 2016-10-12 | 2017-10-12 | Anti-c1s antibodies and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201903012RA true SG11201903012RA (en) | 2019-05-30 |
Family
ID=61906346
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201903012RA SG11201903012RA (en) | 2016-10-12 | 2017-10-12 | Anti-c1s antibodies and methods of use thereof |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US20200048332A1 (en) |
| EP (1) | EP3525583A4 (en) |
| JP (3) | JP7069138B2 (en) |
| KR (2) | KR20240025715A (en) |
| CN (2) | CN110300520B (en) |
| AR (1) | AR110677A1 (en) |
| AU (2) | AU2017341766A1 (en) |
| BR (1) | BR112019007309A2 (en) |
| CA (1) | CA3040253A1 (en) |
| CL (1) | CL2019000975A1 (en) |
| CO (1) | CO2019004741A2 (en) |
| CR (1) | CR20190223A (en) |
| DO (1) | DOP2019000085A (en) |
| EA (1) | EA201990884A1 (en) |
| EC (1) | ECSP19033211A (en) |
| IL (2) | IL265957B2 (en) |
| MX (1) | MX2019004259A (en) |
| PE (1) | PE20191031A1 (en) |
| PH (1) | PH12019500789A1 (en) |
| SG (1) | SG11201903012RA (en) |
| TN (1) | TN2019000109A1 (en) |
| TW (2) | TW202246327A (en) |
| WO (1) | WO2018071676A1 (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3124553A1 (en) | 2012-10-25 | 2014-05-01 | Bioverativ Usa Inc. | Anti-complement c1s antibodies and uses thereof |
| DK2914291T3 (en) | 2012-11-02 | 2022-05-16 | Bioverativ Usa Inc | ANTI-COMPLEMENT-C1S ANTIBODIES AND USES THEREOF |
| LT3280440T (en) | 2015-04-06 | 2023-02-27 | Bioverativ Usa Inc. | Humanized anti-c1s antibodies and methods of use thereof |
| AR121881A1 (en) * | 2020-04-20 | 2022-07-20 | Genzyme Corp | HUMANIZED ANTI-FACTOR BB ANTIBODIES OF COMPLEMENT AND THEIR USES |
| AU2021320870A1 (en) * | 2020-08-06 | 2023-04-06 | Bioverativ Usa Inc. | Inflammatory cytokines and fatigue in subject with a complement mediated disease |
| EP4337332A2 (en) | 2021-07-13 | 2024-03-20 | Mabwell Therapeutics Inc. | Anti-c1s antibodies and uses thereof |
| WO2023245048A1 (en) | 2022-06-15 | 2023-12-21 | Bioverativ Usa Inc. | Anti-complement c1s antibody formulation |
| WO2023250507A1 (en) | 2022-06-24 | 2023-12-28 | Bioverativ Usa Inc. | Methods for treating complement-mediated diseases |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| ATE120761T1 (en) | 1987-05-21 | 1995-04-15 | Creative Biomolecules Inc | MULTIFUNCTIONAL PROTEINS WITH PREDEFINED TARGET. |
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| DE69233482T2 (en) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Method for reducing the immunogenicity of antibody variable domains |
| JP3534749B2 (en) | 1991-08-20 | 2004-06-07 | アメリカ合衆国 | Adenovirus-mediated gene transfer into the gastrointestinal tract |
| WO1993006213A1 (en) | 1991-09-23 | 1993-04-01 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| US5252479A (en) | 1991-11-08 | 1993-10-12 | Research Corporation Technologies, Inc. | Safe vector for gene therapy |
| FR2688514A1 (en) | 1992-03-16 | 1993-09-17 | Centre Nat Rech Scient | Defective recombinant adenoviruses expressing cytokines and antitumour drugs containing them |
| JPH08503855A (en) | 1992-12-03 | 1996-04-30 | ジェンザイム・コーポレイション | Gene therapy for cystic fibrosis |
| CA2115811A1 (en) | 1993-02-17 | 1994-08-18 | Claus Krebber | A method for in vivo selection of ligand-binding proteins |
| JP3532566B2 (en) | 1993-06-24 | 2004-05-31 | エル． グラハム，フランク | Adenovirus vectors for gene therapy |
| RU2162342C2 (en) | 1993-10-25 | 2001-01-27 | Кэнджи Инк. | Recombinant adenoviral vector and methods of its using |
| KR20060099543A (en) | 1994-12-09 | 2006-09-19 | 임페리얼 컬리지 이노베이션스 리미티드 | Identification of genes |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| GB9621680D0 (en) | 1996-10-17 | 1996-12-11 | Oxford Biomedica Ltd | Lentiviral vectors |
| GB2325003B (en) | 1996-10-17 | 2000-05-10 | Oxford Biomedica Ltd | Rectroviral vectors |
| GB9622500D0 (en) | 1996-10-29 | 1997-01-08 | Oxford Biomedica Ltd | Therapeutic gene |
| US6080849A (en) | 1997-09-10 | 2000-06-27 | Vion Pharmaceuticals, Inc. | Genetically modified tumor-targeted bacteria with reduced virulence |
| US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| US6103526A (en) | 1998-10-08 | 2000-08-15 | Protein Sciences Corporation | Spodoptera frugiperda single cell suspension cell line in serum-free media, methods of producing and using |
| GB0105924D0 (en) | 2001-03-09 | 2001-04-25 | Microscience Ltd | Promoter |
| AU2002360355B2 (en) | 2001-11-09 | 2005-07-07 | Government Of The United States Of America, Department Of Health And Human Services | Production of adeno-associated virus in insect cells |
| US9715692B1 (en) | 2003-04-11 | 2017-07-25 | Facebook, Inc. | System for managing bids for pay-per-click search engines |
| EP2221315A1 (en) * | 2003-12-04 | 2010-08-25 | Xencor, Inc. | Methods of generating variant proteins with increased host string content and compositions thereof |
| SG172616A1 (en) * | 2004-04-13 | 2011-07-28 | Hoffmann La Roche | Anti-p-selectin antibodies |
| US8367805B2 (en) * | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| EP1908797B1 (en) | 2005-07-05 | 2012-06-06 | Kaneka Corporation | Methacrylic resin composition |
| FR2897868B1 (en) * | 2006-02-24 | 2012-08-31 | Lab Francais Du Fractionnement | ANTI-IDIOTYPIC ANTIBODIES THAT NEUTRALIZE THE INHIBITORY ACTIVITY OF AN INHIBITORY ANTIBODY DIRECTED AGAINST FIELD C1 OF FACTOR VIII. |
| CA2921594A1 (en) | 2006-06-21 | 2007-12-27 | Uniqure Ip B.V. | Aav vectors with improved rep coding sequences for production in insect cells |
| WO2009020640A2 (en) * | 2007-08-08 | 2009-02-12 | Swarmcast, Inc. | Media player plug-in installation techniques |
| SG10201610247QA (en) * | 2008-12-03 | 2017-02-27 | Genmab As | Antibody variants having modifications in the constant region |
| US8734809B2 (en) | 2009-05-28 | 2014-05-27 | University Of Massachusetts | AAV's and uses thereof |
| DK2561073T3 (en) | 2010-04-23 | 2016-12-12 | Univ Massachusetts | Aav vectors targeted to central nervous system and methods of use thereof |
| CA3124553A1 (en) * | 2012-10-25 | 2014-05-01 | Bioverativ Usa Inc. | Anti-complement c1s antibodies and uses thereof |
| DK2914291T3 (en) | 2012-11-02 | 2022-05-16 | Bioverativ Usa Inc | ANTI-COMPLEMENT-C1S ANTIBODIES AND USES THEREOF |
| AU2014213147B2 (en) * | 2013-01-31 | 2019-01-17 | lmmunAbs Inc. | C5 antibody and method for preventing and treating complement-related diseases |
| ES2784616T3 (en) * | 2013-05-23 | 2020-09-29 | Broteio Pharma B V | Binding molecules that bind to complement factor C2 and their uses |
| EP3019523A4 (en) * | 2013-07-09 | 2016-12-28 | Annexon Inc | Methods of treatment for alzheimer's disease and huntington's disease |
| LT3280440T (en) * | 2015-04-06 | 2023-02-27 | Bioverativ Usa Inc. | Humanized anti-c1s antibodies and methods of use thereof |
-
2017
- 2017-10-12 IL IL265957A patent/IL265957B2/en unknown
- 2017-10-12 JP JP2019519690A patent/JP7069138B2/en active Active
- 2017-10-12 CN CN201780074920.XA patent/CN110300520B/en active Active
- 2017-10-12 AR ARP170102855A patent/AR110677A1/en unknown
- 2017-10-12 CN CN202211195613.6A patent/CN116554320A/en active Pending
- 2017-10-12 EA EA201990884A patent/EA201990884A1/en unknown
- 2017-10-12 KR KR1020247005368A patent/KR20240025715A/en active Application Filing
- 2017-10-12 AU AU2017341766A patent/AU2017341766A1/en not_active Abandoned
- 2017-10-12 TW TW111130089A patent/TW202246327A/en unknown
- 2017-10-12 EP EP17859451.1A patent/EP3525583A4/en active Pending
- 2017-10-12 KR KR1020197013448A patent/KR102638884B1/en active IP Right Grant
- 2017-10-12 US US16/340,991 patent/US20200048332A1/en not_active Abandoned
- 2017-10-12 WO PCT/US2017/056349 patent/WO2018071676A1/en unknown
- 2017-10-12 IL IL308156A patent/IL308156A/en unknown
- 2017-10-12 TW TW106134895A patent/TWI773695B/en active
- 2017-10-12 MX MX2019004259A patent/MX2019004259A/en unknown
- 2017-10-12 PE PE2019000814A patent/PE20191031A1/en unknown
- 2017-10-12 TN TNP/2019/000109A patent/TN2019000109A1/en unknown
- 2017-10-12 CA CA3040253A patent/CA3040253A1/en active Pending
- 2017-10-12 CR CR20190223A patent/CR20190223A/en unknown
- 2017-10-12 SG SG11201903012RA patent/SG11201903012RA/en unknown
- 2017-10-12 BR BR112019007309A patent/BR112019007309A2/en unknown
-
2019
- 2019-04-08 DO DO2019000085A patent/DOP2019000085A/en unknown
- 2019-04-11 CL CL2019000975A patent/CL2019000975A1/en unknown
- 2019-04-11 PH PH12019500789A patent/PH12019500789A1/en unknown
- 2019-05-08 CO CONC2019/0004741A patent/CO2019004741A2/en unknown
- 2019-05-10 EC ECSENADI201933211A patent/ECSP19033211A/en unknown
-
2022
- 2022-04-28 JP JP2022073972A patent/JP7420864B2/en active Active
- 2022-07-12 AU AU2022205174A patent/AU2022205174A1/en active Pending
-
2023
- 2023-07-07 US US18/349,027 patent/US20240076363A1/en active Pending
-
2024
- 2024-01-11 JP JP2024002216A patent/JP2024038319A/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201903012RA (en) | Anti-c1s antibodies and methods of use thereof | |
| SG11201908396PA (en) | Methods of treating tumor | |
| SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
| SG11201807252QA (en) | Anti-lag-3 antibodies | |
| SG11201804161VA (en) | Compositions comprising bacterial strains | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201804510PA (en) | Biparatopic polypeptides antagonizing wnt signaling in tumor cells | |
| SG11201804162WA (en) | Compositions comprising bacterial strains | |
| SG11201807279QA (en) | Binding proteins and methods of use thereof | |
| SG11201806845VA (en) | Moisturizing compositions and uses thereof | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201907583TA (en) | Methods for treating complement-mediated diseases and disorders | |
| SG11201806398YA (en) | Optimized factor viii genes | |
| SG11201810429UA (en) | Anti-cd19 antibody formulations | |
| SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201809594WA (en) | Nicotine particles and compositions | |
| SG11201807549TA (en) | Combination of a cxcr4 antagonist and an immune checkpoint inhibitor | |
| SG11201805204WA (en) | Nicotine particle capsule | |
| SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof | |
| SG11201808525UA (en) | Anti-complement factor bb antibodies and uses thereof | |
| SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
| SG11201900336YA (en) | Radioligands for imaging the ido1 enzyme | |
| SG11201809531SA (en) | BINDING MOLECULES SPECIFIC FOR FCγGAMMA RIIA AND USES THEREOF | |
| SG11201906963QA (en) | Binding agents | |
| SG11201810123SA (en) | Treatment of intrahepatic cholestatic diseases |